|07/19/17||Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi|
|LAKE FOREST, Ill., July 19, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, announced that its shareholders, at a special meeting held earlier today, have overwhelmingly voted to approve the previously announced merger agreement providing for the acquisition of Akorn by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA (FWB:FRE).
The transaction remains subject to regulatory approvals and customary closing conditions, and the... |
|04/24/17||Fresenius Kabi to Acquire Akorn|
|- - - - -
Strategically complementary combination to enhance and diversify Fresenius Kabi’s business and portfolio
- - - - -
At $34.00 a share, transaction valued at approximately $4.3 billion, plus the assumption of debt
- - - - -
Transaction expected to close by early 2018LAKE ZURICH, Ill. and LAKE FOREST, Ill., April 24, 2017 – Fresenius Kabi has agreed to acquire Akorn (NASDAQ: AKRX), a U.S-based manufacturer and marketer of prescription and over-the-counter pharmaceutical... |
|04/07/17||Akorn Confirms Discussions with Fresenius Kabi|
|LAKE FOREST, Ill., April 07, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today confirmed that Akorn is currently in discussions with Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA (FWB:FRE), concerning a potential acquisition of Akorn.
Entry into a formal agreement with respect to a transaction remains subject to, among other things, approval by the Executive Board and Supervisory Board of Fresenius Management SE and t... |